HYPERTENSION, PORTAL
Clinical trials for HYPERTENSION, PORTAL explained in plain language.
Never miss a new study
Get alerted when new HYPERTENSION, PORTAL trials appear
Sign up with your email to follow new studies for HYPERTENSION, PORTAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested to tame dangerous liver pressure
Disease control TerminatedThis study tested if a new drug called Avenciguat, taken alone or with an existing diabetes drug (empagliflozin), could reduce high blood pressure in the main vein leading to the liver. It involved 90 adults with liver cirrhosis from hepatitis B, hepatitis C, or fatty liver disea…
Matched conditions: HYPERTENSION, PORTAL
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
New pill aims to tame dangerous liver pressure
Disease control TerminatedThis study tested if a new oral medicine called Avenciguat could safely reduce high blood pressure in the main vein leading to the liver (portal hypertension) in adults with compensated cirrhosis. About 80 participants were randomly assigned to take one of two doses of the drug o…
Matched conditions: HYPERTENSION, PORTAL
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 02, 2026 15:25 UTC